The Usefulness of F-18 FDG PET/CT-mammography for Preoperative Staging of Breast Cancer: Comparison with Conventional PET/CT and MR-mammography

Overview

Journal Radiol Oncol

Publisher Sciendo

Specialties Oncology
Radiology

Date 2013 Dec 3

PMID 24294185

Citations 3

Authors

Eun-Ha Moon

Seok Tae Lim

Yeon-Hee Han

Young Jin Jeong

Yun-Hee Kang

Hwan-Jeong Jeong

Myung-Hee Sohn

Affiliations

Soon will be listed here.

Abstract

Background: The objective of the study was to compare the diagnostic efficacy of an integrated Fluorine-18 fluorodeoxyglucose (F-18 FDG) PET/CT-mammography (mammo-PET/CT) with conventional torso PET/CT (supine-PET/CT) and MR-mammography for initial assessment of breast cancer patients.

Patients And Methods: Forty women (52.0 ± 12.0 years) with breast cancer who underwent supine-PET/CT, mammo-PET/CT, and MR-mammography from April 2009 to August 2009 were enrolled in the study. We compared the size of the tumour, tumour to chest wall distance, tumour to skin distance, volume of axillary fossa, and number of meta-static axillary lymph nodes between supine-PET/CT and mammo-PET/CT. Next, we assessed the difference of focality of primary breast tumour and tumour size in mammo-PET/CT and MR-mammography. Histopathologic findings served as the standard of reference.

Results: In the comparison between supine-PET/CT and mammo-PET/CT, significant differences were found in the tumour size (supine-PET/CT: 1.3 ± 0.6 cm, mammo-PET/CT: 1.5 ± 0.6 cm, p < 0.001), tumour to thoracic wall distance (1.8 ± 0.9 cm, 2.2 ± 2.1 cm, p < 0.001), and tumour to skin distance (1.5 ± 0.8 cm, 2.1 ± 1.4 cm, p < 0.001). The volume of axillary fossa was significantly wider in mammo-PET/CT than supine-PET/CT (21.7 ± 8.7 cm(3) vs. 23.4 ± 10.4 cm(3), p = 0.03). Mammo-PET/CT provided more correct definition of the T-stage of the primary tumour than did supine-PET/CT (72.5% vs. 67.5%). No significant difference was found in the number of metastatic axillary lymph nodes. Compared with MR-mammography, mammo-PET/CT provided more correct classification of the focality of lesion than did MR-mammography (95% vs. 90%). In the T-stage, 72.5% of cases with mammo-PET/CT and 70% of cases with MR-mammography showed correspondence with pathologic results.

Conclusions: Mammo-PET/CT provided more correct definition of the T-stage and evaluation of axillary fossa may also be delineated more clearly than with supine-PET/CT. The initial assessment of mammo-PET/CT would be more useful than MR-mammography because the mammo-PET/CT indicates similar accuracy with MR-mammography for decision of T-stage of primary breast tumour and more correct than MR-mammography for defining focality of lesion.

Citing Articles

Investigation of Added Value of Imaging Performed in a Prone Position to Standard F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging for Staging in Patients with Breast Cancer.

Erdogan E, Aydin M Mol Imaging Radionucl Ther. 2022; 31(1):23-32.

PMID: 35114748 PMC: 8814550. DOI: 10.4274/mirt.galenos.2021.48343.

Potential Clinical Applications of F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Mammography in Breast Cancer.

Cho I, Kong E Nucl Med Mol Imaging. 2017; 51(3):217-226.

PMID: 28878847 PMC: 5567616. DOI: 10.1007/s13139-016-0446-5.

Thyroid lesions incidentally detected by (18)F-FDG PET-CT - a two centre retrospective study.

Jamsek J, Zagar I, Gaberscek S, Grmek M Radiol Oncol. 2015; 49(2):121-7.

PMID: 26029022 PMC: 4387987. DOI: 10.2478/raon-2014-0039.

References

Orel S, SCHNALL M . MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology. 2001; 220(1):13-30. DOI: 10.1148/radiology.220.1.r01jl3113. View

Beresford M, Lyburn I, Sanghera B, Makris A, Wong W . Serial integrated (18)F-fluorodeoxythymidine PET/CT monitoring neoadjuvant chemotherapeutic response in invasive ductal carcinoma. Breast J. 2007; 13(4):424-5. DOI: 10.1111/j.1524-4741.2007.00454.x. View

Blodgett T, Meltzer C, Townsend D . PET/CT: form and function. Radiology. 2007; 242(2):360-85. DOI: 10.1148/radiol.2422051113. View

Czernin J, Allen-Auerbach M, Schelbert H . Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007; 48 Suppl 1:78S-88S. View

Andersson I, Aspegren K, Janzon L, LANDBERG T, Lindholm K, Linell F . Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. BMJ. 1988; 297(6654):943-8. PMC: 1834636. DOI: 10.1136/bmj.297.6654.943. View

Antoch G, Vogt F, Freudenberg L, Nazaradeh F, Goehde S, Barkhausen J . Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003; 290(24):3199-206. DOI: 10.1001/jama.290.24.3199. View

Heusner T, Freudenberg L, Kuehl H, Hauth E, Veit-Haibach P, Forsting M . Whole-body PET/CT-mammography for staging breast cancer: initial results. Br J Radiol. 2008; 81(969):743-8. DOI: 10.1259/bjr/69647413. View

Thurlimann B, Muller A, Senn H . Management of primary breast cancer: an update. Onkologie. 2004; 27(2):175-9. DOI: 10.1159/000076909. View

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C . Cancer statistics, 2006. CA Cancer J Clin. 2006; 56(2):106-30. DOI: 10.3322/canjclin.56.2.106. View

10.

Tatsumi M, Cohade C, Mourtzikos K, Fishman E, Wahl R . Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 2005; 33(3):254-62. DOI: 10.1007/s00259-005-1835-7. View

11.

Rausch D, Hendrick R . How to optimize clinical breast MR imaging practices and techniques on Your 1.5-T system. Radiographics. 2006; 26(5):1469-84. DOI: 10.1148/rg.265055176. View

12.

Hodolic M . Role of (18)F-choline PET/CT in evaluation of patients with prostate carcinoma. Radiol Oncol. 2012; 45(1):17-21. PMC: 3423714. DOI: 10.2478/v10019-010-0050-8. View

13.

Zangheri B, Messa C, Picchio M, Gianolli L, Landoni C, Fazio F . PET/CT and breast cancer. Eur J Nucl Med Mol Imaging. 2004; 31 Suppl 1:S135-42. DOI: 10.1007/s00259-004-1536-7. View

14.

Kopans D . The positive predictive value of mammography. AJR Am J Roentgenol. 1992; 158(3):521-6. DOI: 10.2214/ajr.158.3.1310825. View

15.

Zebic-Sinkovec M, Hertl K, Kadivec M, Cavlek M, Podobnik G, Snoj M . Outcome of MRI-guided vacuum-assisted breast biopsy - initial experience at Institute of Oncology Ljubljana, Slovenia. Radiol Oncol. 2012; 46(2):97-105. PMC: 3472934. DOI: 10.2478/v10019-012-0016-0. View

16.

Kim J, Jeong Y, Sohn M, Jeong H, Lim S, Kim D . Usefulness of F-18 FDG PET/CT in subcutaneous panniculitis-like T cell lymphoma: disease extent and treatment response evaluation. Radiol Oncol. 2013; 46(4):279-83. PMC: 3572891. DOI: 10.2478/v10019-012-0017-z. View

17.

Hollingsworth A, Stough R, ODell C, Brekke C . Breast magnetic resonance imaging for preoperative locoregional staging. Am J Surg. 2008; 196(3):389-97. DOI: 10.1016/j.amjsurg.2007.10.009. View

18.

Ko B, Noh W, Kang S, Park B, Kang E, Paik N . Changing patterns in the clinical characteristics of korean breast cancer from 1996-2010 using an online nationwide breast cancer database. J Breast Cancer. 2013; 15(4):393-400. PMC: 3542846. DOI: 10.4048/jbc.2012.15.4.393. View

19.

Friedrich M . MRI of the breast: state of the art. Eur Radiol. 1998; 8(5):707-25. DOI: 10.1007/s003300050463. View

20.

Winnekendonk G, Krug B, Warm M, Gohring U, Mallmann P, Lackner K . [Diagnostic value of preoperative contrast-enhanced MR imaging of the breast]. Rofo. 2004; 176(5):688-93. DOI: 10.1055/s-2004-813119. View